. 2023 Apr;15(4):458-464.
doi: 10.1002/dta.3421. Epub 2022 Dec 23.
Affiliations
PMID: 36482504 DOI: 10.1002/dta.3421
TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs
Vivian Delcourt et al. Drug Test Anal. 2023 Apr.
Abstract
Nowadays, numerous websites attempt to commercialize over the internet various products, regardless of the lack of approval by the EMA or the FDA either for human or veterinary use. These products are often produced after aborted drug development due to insufficient or deleterious biological effects, synthesized based on natural products, or only based on scientific literature. However, the administration of such products is dangerous, considering the lack of official control over the production of these substances and the absence of approval by health authorities. In this short communication, we provide an extensive analysis of three misbranded and adulterated products sold over the internet named TB500, TB1000, and SGF1000. We confirm that the content of TB500/TB1000 products is not systematically consistent with it's former descriptions, but also that SGF1000 is mainly composed of sheep extracellular matrix (ECM) and blood proteins, and the signal corresponding to the purported growth promoters is excessively diluted.
Keywords: SGF1000; TB500; doping control; misbranded drugs; non-approved products; thymosin.
© 2022 John Wiley & Sons Ltd.
PubMed Disclaimer
References
REFERENCES
Code US. Title 21 - food and drugs, chapter 9 - federal food, drug, and cosmetic act, subchapter v - drugs and devices, part a - drugs and devices, sec. 351 - adulterated drugs and devices; 2006. https://www.govinfo.gov/content/pkg/USCODE-2011-title21/pdf/USCODE-2011-...
Code US. Title 21 - food and drugs, chapter 9 - federal food, drug, and cosmetic act, subchapter v - drugs and devices, part a - drugs and devices, sec. 352 - misbranded drugs and devices; 2006. https://www.govinfo.gov/content/pkg/USCODE-2015-title21/pdf/USCODE-2015-...
Europa E. Falsified medicines: overview. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-thr...
Krug O, Thomas A, Walpurgis K, et al. Identification of black market products and potential doping agents in germany 2010-2013. Eur J Clin Pharmacol. 2014;70(11):1303-1311.
Thevis M, Schaenzer W. Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls. J Pharm Biomed Anal. 2014;101:66-83.